Repron Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Repron Therapeutics - overview
Established
2023
Location
Milan, -, Italy
Primary Industry
Biotechnology
About
Founded in 2023 and based in Milan, Italy, Repron Therapeutics operates as an epigenetic silencing regulator to intercept and eliminate residual tumor cells at the primary site or micro-metastases in target organs. In June 2023, Repron Therapeutics raised EUR 2 million in seed funding led by Claris Ventures with participation from Consiglio National Research Council(CNR) and San Raffaele Hospital Srl. Repron Therapeutics is a developer of a healthcare technology intended to inhibit the activity of oncogenes on the basis of tumor malignancy through the use of engineered synthetic factors. The company aims to provide treatments for solid tumor cases where complete surgical removal is not feasible, and the risk of metastasis or recurrence is high, providing patients with epigenetic silencing regulations to intercept and eliminate residual tumor cells at the primary site or micro-metastases in target organs.
Current Investors
Claris Ventures, National Research Council (CNR), San Raffaele Hospital Srl
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment
Website
www.reprontherapeutics.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Repron Therapeutics - timeline of key events
Repron Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.